TARA News and Press, ArTara Therapeutics Inc. From 05/15/23

Dosing of first patients follows recent presentation of positive preliminary data from Phase 1a dose escalation portion of ADVANCED-1 trial Company advancing NMIBC clinical development program, with Phase 1b/2 trial in BCG-unresponsive CIS patients and in BCG-naïve and BCG-expose...

2023-05-04 13:36:07 ET Protara Therapeutics press release ( NASDAQ: TARA ): Q1 GAAP EPS of -$0.80. Continue to expect cash, cash equivalents and investments of $90M as of March 31, 2023 to fund operations into 2025 For further details see: Protara Therapeutics GA...

Favorable tolerability and anti-tumor activity observed in NMIBC patients treated with TARA-002 in ADVANCED-1 trial Company plans to initiate ADVANCED-2 trial in BCG-naïve CIS patients and BCG-unresponsive CIS patients in 2H23 Regulatory clearance received from FDA to...

2023-05-02 08:46:59 ET Protara Therapeutics ( NASDAQ: TARA ) received clearance from the U.S. Food and Drug Administration (FDA) to start a trial of TARA-002 to treat children with a rare disease called lymphatic malformations (LMs). LMs are non-cancerous vascular le...

STARBORN-1 trial leverages data from TARA-002 predecessor therapy OK-432, which is approved and has treated thousands of pediatric patients with Lymphatic Malformations in Japan and Taiwan as well as over 500 patients in a compassionate use study completed in the U.S. TARA-002 previously ...

2023-04-28 08:59:54 ET Protara Therapeutics ( NASDAQ: TARA ) has reported encouraging preliminary results from a Phase 1a dose-escalation trial of its investigational cell-based therapy, TARA-002, aimed at treating high-grade non-muscle invasive bladder cancer (NMIBC) patients. ...

Favorable tolerability observed in patients with NMIBC treated with TARA-002 in ADVANCED-1 trial Anti-tumor activity was observed in all three evaluable patients with CIS, including one heavily pre-treated BCG-unresponsive patient who achieved a complete response Company&#...

2023-03-08 09:06:52 ET Protara Therapeutics press release ( NASDAQ: TARA ): Q4 GAAP EPS of -$3.46. Net loss of $39.0 million, compared with a net loss of $10.2 million for the same period in 2021. Net loss in the fourth quarter of 2022 included a non-cash goodwill...

- Data from Phase 1a Portion of ADVANCED-1 Trial of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer Expected in 2Q23 – - Start up Activities for Phase 2 Trial of TARA-002 in Lymphatic Malformations Underway; Trial Initiation Expected 2H23 - - Cash, Cash E...

NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare ...